Abstract
This month’s article covers the period 16 July–15 August 2012. During those 30 days, Human Genome Sciences finally agreed to accept GlaxoSmithKline plc.’s improved offer and be taken over by its long-term partner. The deal was worth approximately US$3.6 billion and represented an improvement of approximately 10% over the initial offer made by GlaxoSmithKline in April 2012. There was also the US approval of Lucentis for the treatment of Diabetic Macular Edema, the first product for this condition to be approved by the US FDA. As ever, the information was largely sourced from company press releases and websites.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
